One blood pressure reading, or the mean of several.

The record that a participant granted or refused one permission, and the index to the page they signed.

The photographed page a participant signed, referenced by the consent it evidences.

Any document held by the study, in the form common to all of them.

A request for a laboratory investigation arising from the screening visit.

What a laboratory returned for one participant, gathering the individual results.

A clinic within a study site, where participants are approached.

Any measurement taken from a participant during the screening visit.

A hospital running the study, or another party to it.

A study participant as held within a site tenant.

A study participant in the form transferred out of a site tenant.

A member of the study team.

A diagnosis the participant reports at interview.

One medicine the participant reports taking at the time of the visit.

The retinal photographs taken from one participant, one series per eye.

A blood or urine sample drawn from a participant for the study's laboratory investigations.

The single visit at which a participant is screened, measured and photographed, or one dated part of it.

A country's approved protocol, and the parties, sites and targets it names.

One participant's enrolment onto one country's protocol, and the consent that permitted it.

Participant age in completed years at the time of enrolment.

Which of the study's blood pressure monitors took the reading.

Whether the reading was taken before or after retinal capture.

Which of the three blood pressure readings this is.

Identifies the site tenant that owns the resource.

The monitors the protocol names.

Before or after retinal capture.

The permissions a Healthy Route participant is asked to grant.

The form a medicine is supplied in.

Right or left.

How often a dietary habit occurs.

The UCUM units a site's laboratory may report the study's results in.

How often a medicine is taken.

How a medicine is taken.

How physically demanding a person's work is.

Reactive or non-reactive.

Permitted results for urine dipstick protein, as printed on the data collection tool.

Current, past or nil.

The visit and its dated parts.

The monitors the protocol names, selected by participant size.

Whether a blood pressure reading was taken before or after retinal capture.

The permissions a Healthy Route participant is asked to grant, each recorded as a separate Consent.

The form a medicine is supplied in. Provisional.

Which eye. The programme does not license SNOMED CT, so laterality takes a local code rather than the SNOMED codes the base resource suggests.

How often a dietary habit occurs. Provisional: the wording follows the Uganda data collection tool and awaits the study team's confirmation.

Codes for the questions on the visit forms that LOINC does not cover, and for the values the study derives from them.

How often a medicine is taken. Provisional.

How a medicine is taken. Provisional.

How physically demanding a person's work is. Provisional: the wording follows the Uganda data collection tool and awaits the study team's confirmation.

The result of a screening test as the laboratory reports it.

The ordinal scale printed on the study's data collection tool for urine dipstick protein.

Whether a person currently uses something, used to, or never has. The history form asks it of alcohol and tobacco.

The visit, and the parts of it that carry their own date.

The value carried forward to analysis, with derivedFrom naming the readings it used. Here it is the mean of the second and third, which is one protocol's rule; the other averages all three. The rule belongs to the study, and what is recorded here is which readings were actually used, so the calculation can be checked rather than trusted.

The first of three readings. Timing matters: one protocol positions its readings relative to the retinal photography.

The second reading. One protocol discards the first and takes the mean of readings two and three.

The third reading.

The venous blood the creatinine and HbA1c were measured on. Its collection time is what the 28-day window is checked against, and what the results refer to.

One permission, recorded as its own resource so that it can be withdrawn without touching the permissions the participant kept.

The general out-patient clinic of the example site, recorded separately from the renal clinic because the two recruit from populations with different disease prevalence.

A participant as held within a site tenant, carrying the identifiers the site needs to recognise them on return.

A participant who consented and was then found ineligible. This is a recorded outcome with a count attached to it, not an absence of data, and it is distinguishable here from a withdrawal and from an enrolment still in progress.

The nephrology clinic of the example site. Participants approached here are drawn from a population with a higher prevalence of chronic kidney disease than the site as a whole.

The single cross-sectional visit at which everything is collected. The clinic is recorded because disease prevalence differs between clinics, and predictive values move with prevalence.

A teaching hospital acting as a study site, holding its own data partition and the paper records of its participants.

A nurse on the delegation log, trained to take consent and to capture retinal images.

One country's approved protocol, sponsored by a local clinician, with a pharmaceutical collaborator funding the analysis and receiving the exported data.

A second country's protocol, structurally identical to country A and differing in region, sponsor and period. Both instances reference the same example site, because the guide defines one; the real studies run three sites and two respectively.

The day the retina was photographed, as a part of the visit with its own date.

The day the blood and urine were drawn, as a part of the visit with its own date. Here it is the visit day; the protocols allow it up to 28 days after consent.

The protocols define type 2 diabetes as HbA1c above 6.5% or on the basis of clinical history.

The answer to the diabetes question on the history form, kept under its item code.

A coded answer on the study's use-status scale, under the LOINC code whose meaning the question has.

What the laboratory returned, gathering the four results it issued together. issued is separate from effective: the interval between a sample being drawn and a result being released is what a site is asked about once the participant has left.

What the Yes on the history form asserts. The interview does not ask the type, so the code is diabetes of unspecified type. Unconfirmed, because nothing in the study checks it against a record, and traceable to the answer through evidence.

One medicine from the medications form. The catalogue entry identifies the product with its strength and form; how it is taken is on the study's own scales.

One order covering the blood and urine investigations the protocol specifies. authoredOn carries its own timestamp so that ordering before consent is detectable.

The material the algorithm under validation consumes. One series per eye, each carrying its own laterality, because a prediction attributed to the wrong eye is not detectable after the fact.

The measured value the eGFR is calculated from.

Measured for risk stratification. One protocol states explicitly that it is not used for exclusion.

A coded ordinal result on the scale printed on the data collection tool. In one protocol this gates eligibility; in the other it is the comparator the algorithm is measured against, and is recorded for every participant regardless of the result.

The spot urine the dipstick and the albumin-to-creatinine ratio were measured on.

A calculated value, not a measured one. derivedFrom names the creatinine it was computed from and method names the equation, because neither is recoverable from the number. LOINC 98979-8 is the 2021 revision with the race coefficient removed; 62238-1 is the generic CKD-EPI code and would understate what was done.